Work

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps4196

Authors: Sherise C. Rogers, Brian Hemendra Ramnaraign, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Anita Ahmed Turk, Karen Bullock Russell, Ibrahim Nassour, Ahmad El-Far, Jesus C. Fabregas, Ryan M. Thomas, Ilyas Sahin, Carmen Joseph Allegra, David L. DeRemer, Thomas J. George

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Florida, UF Health Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, United States Navy, Orlando Health, University of Miami, Sylvester Comprehensive Cancer Center, Augusta University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286294399

Cites:

Cited by:

Related to: 10